Virbac Stock Surpasses Its 50-Day Moving Average, Reaching 356 Euros
On Wednesday, shares of the animal health specialist were priced at 356 euros, showing a significant increase from the previous day's close of 347.50 euros. This progress occurred during an exceptionally dynamic session in Paris, with the CAC 40 surging by more than 4.5%. Over the past year, Virbac has maintained a solid performance, nearly 27%.
Significant Movement Above the 50-Day Moving Average
During the session, Virbac significantly exceeded its 50-day moving average, currently at 354.06 euros, after fluctuating around this level in recent days. The stock is also well above its 200-day moving average (344.10 euros), reinforcing the medium-term upward trend. The RSI, at 46, remains in the neutral zone and does not indicate overbuying or overselling, leaving room for progression before reaching technical tension levels. Regarding the Bollinger Bands, the price is in the upper part of the channel, at 77% of the range between the lower bound (329.41 euros) and the upper bound (364.09 euros). The nearest resistance is at 370 euros: crossing this threshold could lead to further acceleration. The major support identified at 328.50 euros remains distant from the current price, indicating a comfortable safety cushion at this stage.
Focus Shifts to Upcoming Financial Reports
Attention is now turning to the upcoming publication of the first quarter 2026 revenue, expected on April 16th. This date represents the next fundamental catalyst for the stock, in a context where quarterly performance has remained nearly stable over three months (-0.84%). The general assembly is scheduled for June 26, followed by the second quarter revenue on July 20 and the half-year results on September 17. The stock has a particularly low beta of 0.06, indicating a significant decoupling from major indices. This characteristic partly explains why today's increase remains modest compared to the CAC 40, which is up 4.58% in the session at 8,270.70 points, or the SBF 120, up 4.52%. In the health sector, dynamics vary: Sanofi is down by 0.20% while UCB is up by 1.67%. Virbac's monthly volatility, contained at 7.01, confirms the stock's defensive profile in a volatile market.
